Article Information
History
- April 15, 2021.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Gennaro Pagano1,*,
- Frank G Boess1,
- Kirsten I Taylor1,2,
- Benedicte Ricci3,
- Brit Mollenhauer4,5,
- Werner Poewe6,
- Anne Boulay7,
- Judith Anzures-Cabrera8,
- Annamarie Vogt1,
- Maddalena Marchesi3,
- Anke Post9,
- Tania Nikolcheva10,
- Gene G Kinney11,
- Wagner M Zago11,
- Daniel K Ness11,
- Hanno Svoboda1,
- Markus Britschgi1,
- Susanne Ostrowitzki10,
- Tanya Simuni12,
- Kenneth Marek13,
- Martin Koller11,
- Jeff Sevigny14,
- Rachelle Doody10,
- Paulo Fontoura10,
- Daniel Umbricht1,
- Azad Bonni1,
- PASADENA Investigators,
- Prasinezumab Study Group
- ↵*Correspondence:
Corresponding author: Gennaro Pagano MD, PhD, Expert Medical Director & Group Leader in Neuroscience and Rare Diseases, Roche Pharma Research and Early Development (pRED), F. Hoffmann-La Roche Ltd, Basel, Switzerland, Email:
gennaro.pagano{at}roche.com
- 1Roche Pharma Research and Early Development (pRED), Neuroscience and Rare Diseases Discovery and Translational Area, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland
- 2Faculty of Psychology, University of Basel, Basel, Switzerland
- 3Roche Pharma Research and Early Development (pRED), Pharmaceutical Sciences, Roche Innovation Center, F. Hoffmann-La Roche Ltd, Basel, Switzerland
- 4Paracelsus-Elena-Klinik, Kassel, Germany
- 5Department of Neurology, University Medical Center Göttingen, Göttingen, Germany
- 6Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
- 7Idorisa Pharmaceuticals Ltd, Allschwil, Switzerland
- 8Roche Products Ltd, Welwyn Garden City, UK
- 9Feetme SAS, Paris, France
- 10F. Hoffmann-La Roche Ltd, Basel, Switzerland
- 11Prothena Biosciences Inc, South San Francisco, CA, USA
- 12Department of Neurology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
- 13Institute for Neurodegenerative Disorders, New Haven, CT, USA
- 14Prevail Therapeutics, New York, USA